Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated.
Rappersberger K, Komar M, Ebelin ME, Scott G, Burtin P, Greig G, Kehren J, Chibout SD, Cordier A, Holter W, Richter L, Oberbauer R, Stuetz A, Wolff K.
Rappersberger K, et al. Among authors: greig g.
J Invest Dermatol. 2002 Oct;119(4):876-87. doi: 10.1046/j.1523-1747.2002.00694.x.
J Invest Dermatol. 2002.
PMID: 12406334
Free article.
Clinical Trial.